Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
ConditionIntracranial Neoplasm
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age4+
SponsorThomas Hope
About this trial
This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.
Eligibility criteria
Qualifiers
Population 1: Participants after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on MRI.
Recurrent metastatic lesions.
Recurrent high-grade gliomas (Grades 3 and 4).
Recurrent low-grade gliomas (Grade 2).
Disqualifiers
Participants with known incompatibility to PET or Computerized tomography (CT)/magnetic resonance imaging (MRI) scans.
Participants unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.
Sedation or anesthesia can be used for participants who cannot tolerate the exam.
Trial design
Treatments tested in this trial
- Fluorethyltyrosine (18-F)
- Positron Emission Tomography (PET)
Treatment groups
199 Participants
are divided into 2 treatment groupsSponsors and collaborators
Thomas Hope
Lead sponsor
University of California, San Francisco
Sponsor institution
Source ClinicalTrials.gov